GeneTex
United States (US)

Caveolin 3 blocking peptide

Cat No. GTX88437-PEP

Application ELISA, Apuri, Blocking
Species Human
APPLICATION

Application Note

*Optimal dilutions/concentrations should be determined by the researcher.
Application Dilution
ELISA Assay dependent
Apuri Assay dependent
Blocking Assay dependent
Not tested in other applications.

Specificity/Sensitivity

The peptide was used in the production of GTX88437.
PROPERTIES

Form

Lyophilized powder

Buffer

Lyophilized from 5% (v/v) acetonitrile/H₂O. Reconstitute pellet in 200μl distilled water to obtain a 0.5mg/ml peptide solution.

Note

For In vitro laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
TARGET

Synonyms

LQT9 blocking peptide , VIP21 blocking peptide , CAV3 blocking peptide , LGMD1C blocking peptide

Background

This gene encodes a caveolin family member, which functions as a component of the caveolae plasma membranes found in most cell types. Caveolin proteins are proposed to be scaffolding proteins for organizing and concentrating certain caveolin-interacting molecules. Mutations identified in this gene lead to interference with protein oligomerization or intra-cellular routing, disrupting caveolae formation and resulting in Limb-Girdle muscular dystrophy type-1C (LGMD-1C), hyperCKemia or rippling muscle disease (RMD). Alternative splicing has been identified for this locus, with inclusion or exclusion of a differentially spliced intron. In addition, transcripts utilize multiple polyA sites and contain two potential translation initiation sites. [provided by RefSeq, Jul 2008]
Show More +

Research Area